الفهرس 
Introduction and Aim of The WorkOnly 14 pages are availabe for public view
 |  | from | 188 |  |  |
| | | from | 188 | | |
Abstract
Autologous PBSCT have been increasingly used in place of BMT. It is now possible to conclude that PBSC are undoubtedly capable of restoring short term hematopoiesis when reinfased after myelo-ablative chemotherapy or even more rapidly than bone marrow stem cells provided that they have been previously collected in sufficient amounts. High dose therapy with BM or PBSC support is a high technology technique usually administered in specialized centers. The use of PBSC has made this technique simpler and accessible also to smaller hospitals. Patients with relapsed or refractory lymphoma only have chance of cure below 10% with conventional chemotherapy. Despite the curative i potential of HDC with autologous stem cell infusion, many patients do not have access to this therapy because of geographic barriers, high cost Associated with treatment and the perception that the morbidity and Mortality of treatment requires referral to tertiary bone marrow transplant center. The aim of this work was bifocal; first, to find simple, less expensive and effective protocol for HDC with suitable stem cell.